[go: up one dir, main page]

ES2061688T3 - Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion. - Google Patents

Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.

Info

Publication number
ES2061688T3
ES2061688T3 ES88310560T ES88310560T ES2061688T3 ES 2061688 T3 ES2061688 T3 ES 2061688T3 ES 88310560 T ES88310560 T ES 88310560T ES 88310560 T ES88310560 T ES 88310560T ES 2061688 T3 ES2061688 T3 ES 2061688T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
absorption
glicirricinate
calcitonine
improver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88310560T
Other languages
English (en)
Inventor
Valerio Aliverti
Teodoro Fonio
Luciano Dorigotti
Mario Pinza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SMITHKLINE BEECHAM FARMA
GlaxoSmithKline SpA
Original Assignee
SMITHKLINE BEECHAM FARMA
Smithkline Beecham Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT22647/87A external-priority patent/IT1223132B/it
Priority claimed from IT8819541A external-priority patent/IT1216762B/it
Application filed by SMITHKLINE BEECHAM FARMA, Smithkline Beecham Farmaceutici SpA filed Critical SMITHKLINE BEECHAM FARMA
Application granted granted Critical
Publication of ES2061688T3 publication Critical patent/ES2061688T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

EL INVENTO RELATA A COMPOSICIONES FARMACEUTICAS QUE COMPRENDE CALCITOMIN Y UN GLICIRICINATO INCREMENTADOR DE ABSORCION. LAS COMPOSICIONES REFERIDAS ESTAN ADAPTADAS PARA ADMINISTRACION NASAL, POR EJEMPLO SPRAYS NASALES.
ES88310560T 1987-11-13 1988-11-10 Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion. Expired - Lifetime ES2061688T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT22647/87A IT1223132B (it) 1987-11-13 1987-11-13 Composizione farmaceutica per somministrazione nasale
IT8819541A IT1216762B (it) 1988-02-25 1988-02-25 Composizione farmaceutica per somministrazione nasale.

Publications (1)

Publication Number Publication Date
ES2061688T3 true ES2061688T3 (es) 1994-12-16

Family

ID=26327206

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88310560T Expired - Lifetime ES2061688T3 (es) 1987-11-13 1988-11-10 Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.

Country Status (7)

Country Link
US (1) US5183802A (es)
EP (1) EP0327756B1 (es)
DE (1) DE3887494T2 (es)
ES (1) ES2061688T3 (es)
GB (1) GB2212062B (es)
IE (1) IE61913B1 (es)
MX (1) MX9203725A (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1238072B (it) * 1990-01-19 1993-07-03 Sclavo Spa Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
JPH078806B2 (ja) * 1990-08-16 1995-02-01 旭化成工業株式会社 カルシトニン類含有経鼻投与用乳剤
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
IT1251685B (it) * 1991-10-11 1995-05-19 Isf Spa Composizioni farmaceutiche contenenti una calcitonina
CA2125400A1 (en) * 1991-12-18 1993-06-24 Gordon L. Amidon Soybean protein or hydrolyzates in pharmaceutical compositions to protect bioactive peptides from enzymatic inactivation
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US6153592A (en) * 1992-11-09 2000-11-28 Port Systems, Llc Enhancing the bioavailability of proteolytically labile therapeutic agents
GR1001447B (el) * 1992-12-08 1993-12-30 Ron Poulenk Rorer Anonymos Emp Φαρμακευτικά προιόντα για την χορήγηση καλτσιτονίνης ενδορινικώς.
EP0726075A1 (en) * 1995-02-08 1996-08-14 Therapicon Srl Pharmaceutical non-inorganic saline solutions for endonasal administration
US6190699B1 (en) 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
DE60042057D1 (de) * 1999-01-29 2009-06-04 Esperanza Peptide Ltd Bukkales verabreichungssystem für proteinhaltige medikamente
US6197328B1 (en) * 1999-08-20 2001-03-06 Dott Research Laboratory Nasally administrable compositions
AU783952B2 (en) 2000-02-04 2006-01-05 Unigene Laboratories, Inc. Nasal calcitonin formulations
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20030218106A1 (en) * 2000-08-16 2003-11-27 Juergen Pensel Folding stand
ITRM20010048A1 (it) 2001-01-30 2002-07-30 Gregorio Mauro De Metodo per preparare soluzioni acquose fisiologicamente accettabili esoluzioni cosi' ottenute.
JP2004522802A (ja) * 2001-02-16 2004-07-29 ラヴィファーム・ラボラトリーズ・インク 水溶性で風味良い複合体
US7812120B2 (en) * 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
DE102010028365A1 (de) 2010-04-29 2011-11-03 Lichtblick Gmbh Verwendung einer Phospholipid enthaltenden Zusammensetzung zur Entfernung von subkutanen Fettansammlungen
US10723716B2 (en) 2016-12-21 2020-07-28 New York University Alpha-helix mimetics as modulators of Abeta self-assembly
US11124479B2 (en) 2017-07-14 2021-09-21 New York University Oligopyrroles as antagonists of islet amyloid polypeptide oligomerization
US10500197B2 (en) 2017-07-18 2019-12-10 New York University Use of oligopyridylamides to inhibit mutant p53 amyloid formation and restore its tumor suppressor function
US11975106B2 (en) * 2020-03-26 2024-05-07 Provectus Pharmatech, Inc. Uses of halogenated xanthenes in oncology and virology

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH532452A (de) * 1970-07-02 1973-01-15 Esterol Ag Verfahren zur Herstellung von kunstharzgebundenen Formkörpern, insbesondere von polyestergebundenen Schleifkörpern
CH594608A5 (es) * 1973-12-14 1978-01-13 Ciba Geigy Ag
US3988309A (en) * 1973-12-27 1976-10-26 Toyo Jozo Kabushiki Kaisha EEL calcitonin
JPS51128993A (en) * 1975-05-01 1976-11-10 Tanpakushitsu Kenkyu Shiyoureikai Process for preparing new polypeptides
GB2008403B (en) * 1977-11-04 1982-07-28 Christie R B Parsons J A Pharmaceutical compositions
US4304692A (en) * 1978-07-24 1981-12-08 Armour Pharmaceutical Company Synthesis of biologically active peptides
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
US4393200A (en) * 1980-01-09 1983-07-12 Maruzen Kasei Kabushiki Kaisha 18 α-Glycyrrhizinic acid and salt thereof
EP0037943B1 (en) * 1980-03-31 1985-08-14 Teijin Limited Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
IL65184A0 (en) * 1982-03-05 1982-05-31 Yissum Res Dev Co Preparation for the treatment of oral diseases,comprising glycyrrhizin
EP0094157B1 (en) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its use
GB2127689B (en) * 1982-10-05 1986-07-09 Sandoz Ltd Calcitonin inhalation compositions
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
AU572815B2 (en) * 1982-12-29 1988-05-19 Armour Pharmaceutical Company Pharmaceutical calcitonin compositions for intranasal application
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
EP0187433B1 (en) * 1983-08-01 1990-12-27 Teijin Limited Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
US4597900A (en) * 1983-08-22 1986-07-01 Armour Pharmaceutical Co. Des2 -glycine8 -des22 -calcitonin
JPS6160620A (ja) * 1984-09-03 1986-03-28 Teijin Ltd ピログルタミン酸エステル類を含有する医薬品組成物
JPS61126034A (ja) * 1984-11-26 1986-06-13 Yamanouchi Pharmaceut Co Ltd アルド−スを含有するカルシトニン経鼻剤
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
US4692441A (en) * 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US4731360A (en) * 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
JPH085800B2 (ja) * 1986-12-19 1996-01-24 エーザイ株式会社 塩化リゾチ−ム及びグリチルリチン酸ジカリウム含有水溶液製剤
CA1335076C (en) * 1987-04-01 1995-04-04 Hanna R. Kowarski Pharmaceutical composition and method for intranasal administration

Also Published As

Publication number Publication date
EP0327756A3 (en) 1990-10-03
IE883390L (en) 1989-05-13
US5183802A (en) 1993-02-02
EP0327756B1 (en) 1994-01-26
GB2212062A (en) 1989-07-19
GB8826321D0 (en) 1988-12-14
IE61913B1 (en) 1994-11-30
DE3887494D1 (de) 1994-03-10
EP0327756A2 (en) 1989-08-16
MX9203725A (es) 1992-09-01
DE3887494T2 (de) 1994-05-19
GB2212062B (en) 1991-07-17

Similar Documents

Publication Publication Date Title
ES2061688T3 (es) Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
PA8435001A1 (es) Derivados 6,6-heterobiciclicos sustituidos.
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
SV1995000042A (es) Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv
ES2164182T3 (es) Benzociclopentanoxazolidinonas que contienen heteroatomos con actividad antibacteriana.
ES2071486T3 (es) Derivado de la 5h-pirrolo(3,4-b)pirazina opticamente activa, su preparacion y las composiciones farmaceuticas que le contienen.
DE3586545D1 (de) Erhoehte schmerzlosigkeit bewirkende pharmazeutische zusammensetzungen.
MX9305769A (es) Nuevos derivados de analogos del taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
BR9611802A (pt) Composições farmacêuticas
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
ES2098140T3 (es) Liosferas que contienen gonadotropina.
ES2058799T3 (es) Composiciones estabilizadas que contienen factor de crecimiento epidermico.
MX9203394A (es) Benzazepinas substituidas, su preparacion y composiciones farmaceuticas que contienen las mismas.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2070981T3 (es) Concentrados de componente activo y nuevas combinaciones de componente activo de hojas de ginkgo biloba, sus metodos de preparacion y productos farmaceuticos que contienen los concentrados de componente activo o las combinaciones de componente activo.
ES2146297T3 (es) Nuevos derivados del benzopirano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2040727T3 (es) Un proceso para preparar una formulacion en aerosol en solucion de un analogo.
ES2044840T3 (es) Composiciones estabilizadas del activador del plasminogeno de tejido humano.
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
MX9207494A (es) 4(5)-amino-1,8-naftiridinas substituidas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
MX9207394A (es) Esteroides de 17-espirofuran-3'-ilideno.
ES2158496T3 (es) Mezclas aislables a partir de granos de eugenia jambolana lamarck, su preparacion y la utilizacion de estas mezclas y de algunos de sus constituyentes como medicamentos.
ES2056288T3 (es) Absorbente de oxigeno.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 327756

Country of ref document: ES